healthy older people not developed alzheimer presumption carried kind protective factors immune systems not completely clear aducanumab works study shows targets amyloid brain not bloodstream hypothesis suggests antibodies attack amyloid bloodstream sidetracked never brain focusing brain amyloid aducanumab able cross brain reach target researchers said press conference larger studies participants start lower dose minimize risk aria likely occur early treatment people carry copy alzheimer risk gene vulnerable aria probably remain lower dose according salloway participants evidence excessive amounts amyloid brains shown pet scan allowed study help avoid problem doomed earlier drug trials trials failed researchers think included people excessive amyloid